Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Potential threat of smallpox bioterrorism and concerns related to the adverse effects of currently licensed live-virus vaccines suggest the need to develop novel vaccines with better efficacy against smallpox. Use of DNA vaccines containing specific antigen-encoding plasmids prevents the risks associated with live-virus vaccines, offering a promising alternative to conventional smallpox vaccines. In this study, we investigated the efficiency of toll-like receptor (TLR) ligands in enhancing the immunogenicity of smallpox DNA vaccines. BALB/c mice were immunized with a DNA vaccine encoding the vaccinia virus L1R protein, along with the cytosine-phosphate-guanine (CpG) motif as a vaccine adjuvant, and their immune response was analyzed. Administration of B-type CpG oligodeoxynucleotides (ODNs) as TLR9 ligands 24 h after DNA vaccination enhanced the Th2-biased L1R-specific antibody immunity in mice. Moreover, B-type CpG ODNs improved the protective effects of the DNA vaccine against the lethal Orthopoxvirus challenge. Therefore, use of L1R DNA vaccines with CpG ODNs as adjuvants is a promising approach to achieve effective immunogenicity against smallpox infection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12033-023-00800-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel Nanoadjuvant for Subunit Vaccines: Cyclic Seven-Membered Tertiary Amine-Based Polymer-Grafted Ethoxy-Acetalated Dextran Nanoparticles Encapsulating CpG Oligodeoxynucleotides.
Mol Pharm
August 2025
National Glycoengineering Research Center, Shandong Key Laboratory of Carbohydrate and Carbohydrate-conjugate Drugs, NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-based Medicine, Shandong University, Qingdao 266237, China.
CpG oligodeoxynucleotides (ODNs) are synthetic Toll-like receptor 9 (TLR9) agonists that promote Th1-biased immune responses. However, their clinical utility is limited by rapid nuclease degradation and poor cellular uptake in antigen-presenting cells (APCs). To overcome this, we developed a pH-responsive nanoadjuvant, Ace-Dex-PC7A@CpG, composed of a cyclic seven-membered tertiary amine-based polymer (PC7A) grafted onto ethoxy-acetalated dextran (Ace-Dex) encapsulating CpG ODN 1668.
View Article and Find Full Text PDFDesign and Characterization of an Anti-Clec9a Antibody Armed with CpG Oligonucleotides To Enable Targeted Delivery of Adjuvant to Cross-Presenting Dendritic Cells.
ACS Chem Biol
August 2025
Bristol-Myers Squibb Research & Development, 700 Bay Road, Redwood City, California 94063, USA.
C-type lectin receptor, Clec9a, is a highly specific receptor expressed on cross-presenting conventional dendritic cells (cDC1). This receptor specificity for this rare population of dendritic cells (DCs), combined with their inherent ability to internalize and localize to the endocytic compartment, presents a unique opportunity for targeted delivery of innate immune agonists. By leveraging an anti-Clec9a antibody, we can specifically deliver these agonists to cross-presenting cDCs, thereby enhancing the cross-priming and expansion of tumor-specific cytotoxic T lymphocytes (CTLs).
View Article and Find Full Text PDFInnovative microbial strategies in atopic dermatitis.
Front Immunol
August 2025
Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.
Atopic dermatitis (AD) is characterized by chronic and recurrent itching with a high burden of disability-adjusted life years (DALYs, a measure of overall disease burden). Traditional treatments mainly include corticosteroids, which have a good effect on controlling inflammation but adverse side effects. Recently, advancements in understanding the pathogenesis of AD have led to the emergence of a variety of novel therapeutic approaches, such as microbiome manipulation, offering renewed hope for more effective management of this condition.
View Article and Find Full Text PDFMethylated CpG ODNs from subsp. Modulate Treg Induction and Suppress Allergic Response in a Murine Model.
Int J Mol Sci
July 2025
Department of Microbiology & Immunology, Georgetown University Medical Center, Washington, DC 20057, USA.
In our previous studies, methylated CpG oligodeoxynucleotides (ODN) derived from subsp. have demonstrated immunomodulatory effects through the induction of regulatory T cells (Tregs). To define the structural determinants underlying this effect, we synthesized four CpG ODNs varying in methylation degree, CpG motif placement, and backbone length.
View Article and Find Full Text PDFMultivalent Co-assembly of LL37-CpG nanoparticles: Enhanced immune response through activating multiple cell internalization pathways.
Mater Today Bio
August 2025
Songshan Lake Materials Laboratory, Dongguan, 523808, Guangdong, China.
Recent studies have demonstrated that the human antimicrobial peptide LL37 plays a critical role in immune regulation under both normal physiological conditions and during disease progression, as evidenced by its elevated levels observed in various chronic inflammatory diseases. A deeper understanding of its mechanism is essential for elucidating associated physiological and pathological processes, as well as for designing effective immune adjuvants and clinical therapeutics. In this study, we report that LL37 facilitates the assembly of unmethylated CpG dinucleotides (CpG ODNs), a clinically relevant immune adjuvant, into non-crystalline nanoparticles (NPs) with controlled size and zeta potential in a charge ratio-dependent manner.
View Article and Find Full Text PDF